Biotechnology Stocks

What are the key growth drivers for the Indian biotech sector?

Growth is driven by increasing R&D expenditure, government support through schemes like PLI, a focus on biosimilars and novel drug discovery, contract research opportunities, and rising demand for affordable healthcare solutions globally.

How is the Indian biotech sector different from the pharmaceutical sector?

While overlapping, biotech focuses more on biological processes and organisms for drug development (biologics, biosimilars, gene therapy), often involving higher R&D risks and longer gestation periods. Pharma traditionally focuses on small molecule drugs and generics.

What are the risks associated with investing in biotech stocks?

Key risks include high R&D failure rates, long and uncertain drug development timelines, stringent regulatory hurdles (USFDA, EMA approvals), intense competition, and patent cliffs. Valuations can be volatile based on trial outcomes.

Which metrics should investors focus on for biotech companies?

Investors should focus on R&D pipeline progress, clinical trial success rates, regulatory approval status, patent expiries, management expertise, and the company's cash burn rate alongside its funding runway.